Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PolyPid Ltd. (PYPD) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5.13, with a market capitalisation of $108.26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.06 to $5.73. This page covers its latest market performance, valuation, price trends and company information.
$108.26M | |
$5.32 | |
$583.50 | |
$2.30 | |
$5.33 | |
80.87K | |
216.16K | |
-- | |
$5.73 | |
$3.06 | |
-- | |
-- |
PolyPid Ltd. (PYPD) is trading at $5.32 in pre-market trading as of 2026-09-15 23:48:00, down 0.28% ($0.01) from the previous close of $5.33
Pre-market trading shows how investors are pricing PYPD before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, PolyPid Ltd. (PYPD) moved from $5.39 to $5.13, representing a decline of 4.92% ($0.26).
The stock traded between $5.03 and $5.57 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 104.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 77.3%
PYPD is currently trading at $5.13, placing it 77.3% of the way from its 52-week low of $3.06 to its 52-week high of $5.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PolyPid Ltd. (PYPD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.